MAXCYTE, INC.(MXCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,868 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MXCT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MAXCYTE, INC. (MXCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MXCT at 14.3/100 on a 32-signal composite quality model, placing it at rank #2,868 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (5.4) and profitability (7.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MAXCYTE, INC. reports quarterly revenue of $7.3M, net income of $-8.9M, free cash flow of $-4.7M. Top institutional holders of MXCT by reported 13-F value include Capricorn Fund Managers Ltd, Vitruvian Partners LLP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MXCT trades on the Nasdaq exchange and files with the SEC under CIK 1287098. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MXCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MAXCYTE, INC. directly from SEC EDGAR. MAXCYTE, INC.'s 13F Pro composite quality score has ranged between 11 and 35 since 2022, currently 14.3 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.3M
Net Income
Q2 2026
$-8.9M
Free Cash Flow
Q2 2026
$-4.7M
ROIC
Q2 2026
-25.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-14.5% YoYNet Income
-8.7% YoYOperating Income
-1.4% YoYEPS (Diluted)
-7.7% YoYTotal Assets
-15.4% YoYOp. Cash Flow
-24.6% YoYFree Cash Flow
-23.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $33.0M -14.5% | $38.6M -6.4% | $41.3M -6.7% | $44.3M +30.6% | $33.9M +29.5% | $26.2M |
| Net Income | $-44.6M -8.7% | $-41.1M -8.3% | $-37.9M -60.9% | $-23.6M -23.5% | $-19.1M -61.5% | $-11.8M |
| Operating Income | $-51.9M -1.4% | $-51.2M -6.0% | $-48.3M -76.5% | $-27.4M -50.4% | $-18.2M -64.5% | $-11.1M |
| EPS (Diluted) | $-0.42 -7.7% | $-0.39 -5.4% | $-0.37 -60.9% | $-0.23 -9.5% | $-0.21 -23.5% | $-0.17 |
| Total Assets | $202.5M -15.4% | $239.5M -10.7% | $268.3M -6.4% | $286.7M +0.9% | $284.1M +448.7% | $51.8M |
| Operating Cash Flow | $-34.4M -24.6% | $-27.6M -27.3% | $-21.7M -46.7% | $-14.8M -38.4% | $-10.7M -21.6% | $-8.8M |
| Free Cash Flow | $-36.2M -23.6% | $-29.3M -15.3% | $-25.4M +23.7% | $-33.3M -129.2% | $-14.5M -33.7% | $-10.9M |
Get alerted when MXCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MAXCYTE, INC. including:
Top Institutional Holders of MXCT
Capricorn Fund Managers Ltd
$10.1M8,200,000 shVitruvian Partners LLP
$6.2M5,043,356 shVANGUARD CAPITAL MANAGEMENT LLC
$5.0M4,031,284 shMORGAN STANLEY
$4.5M3,694,049 shMudita Advisors LLP
$4.1M3,370,689 shBlackRock, Inc.
$3.8M3,060,960 shBrooklands Fund Management Ltd
$3.7M2,848,083 shBNP Paribas Asset Management Holding S.A.
$3.4M2,773,554 shCADIAN CAPITAL MANAGEMENT, LP
$2.7M2,201,166 shPeapod Lane Capital LLC
$2.6M2,125,752 sh
| Fund | Value | Shares |
|---|---|---|
| Capricorn Fund Managers Ltd | $10.1M | 8,200,000 |
| Vitruvian Partners LLP | $6.2M | 5,043,356 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.0M | 4,031,284 |
| MORGAN STANLEY | $4.5M | 3,694,049 |
| Mudita Advisors LLP | $4.1M | 3,370,689 |
| BlackRock, Inc. | $3.8M | 3,060,960 |
| Brooklands Fund Management Ltd | $3.7M | 2,848,083 |
| BNP Paribas Asset Management Holding S.A. | $3.4M | 2,773,554 |
| CADIAN CAPITAL MANAGEMENT, LP | $2.7M | 2,201,166 |
| Peapod Lane Capital LLC | $2.6M | 2,125,752 |
Companies Similar to MXCT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Metagenomi Therapeutics, Inc.
RxSight, Inc.
DocGo Inc.
PRECISION BIOSCIENCES INC
Pulmonx Corp
Voyager Therapeutics, Inc.
Outset Medical, Inc.
ORASURE TECHNOLOGIES INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MXCT on your watchlist
Track score changes the day MAXCYTE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MXCT a good stock to buy?
13F Pro's AI-powered analysis of MAXCYTE, INC. (MXCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MXCT are available on the MXCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MXCT is classified as a small company.
Which hedge funds own MXCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MXCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MAXCYTE, INC.'s investment landscape.